We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year
Read MoreHide Full Article
Entera Bio (ENTX - Free Report) stock has risen 194.4% this year so far against the industry’s decrease of 5.7%.
Entera Bio’s stock gained this year following announcement of positive final three-month biomarker data from the phase II study of its orally delivered human parathyroid hormone (1-34) or PTH, drug candidate, EB613 in osteoporosis in March.
The study met the primary endpoint, showing a significant increase in the P1NP biomarker in the 2.5 mg dose group after three months of treatment compared to placebo. P1NP is a biomarker that indicates the rate of new bone formation. Patients in the 2.5 mg dose group also experienced a significant reduction in CTX, a biomarker that indicates the rate of bone resorption. The reduction in CTX corresponds with a reduction in the breakdown of bone and is an important factor for a potential increase in bone mineral density (BMD).
The data, overall, supported the osteoanabolic or bone building effects of EB613 as well as its potential to produce meaningful increases in BMD at six months. Final data from the study, including BMD data are expected to be presented in the second quarter.
EB613, if approved, will be the first oral bone building (osteoanabolic) treatment for osteoporosis, thus providing an oral alternative to daily injections, which should improve patient convenience, compliance and outcomes while lowering the total cost of care.
Some better-ranked stocks in the healthcare sector are BioNTech (BNTX - Free Report) , Atea Pharmaceuticals (AVIR - Free Report) and Repligen Corporation (RGEN - Free Report) . While BioNTech has a Zacks Rank of 1, the other two companies carry a Zacks Rank #2 (Buy).
BioNTech’s earnings estimates have risen from $10.91 per share to $29.44 per share for 2021 and from $7.34 per share to $21.34 per share for 2022 in the past 60 days. The stock is up 138.6% this year so far.
Atea’s earnings per share estimates have increased from $3.70 to $8.37 for 2021 and from $16.14 to $17.21 for 2022 over the past 60 days.
Repligen’s earnings estimates have risen from$1.91 to $2.21 for 2021 and from $2.23 to $2.53 for 2022 over the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year
Entera Bio (ENTX - Free Report) stock has risen 194.4% this year so far against the industry’s decrease of 5.7%.
Entera Bio’s stock gained this year following announcement of positive final three-month biomarker data from the phase II study of its orally delivered human parathyroid hormone (1-34) or PTH, drug candidate, EB613 in osteoporosis in March.
The study met the primary endpoint, showing a significant increase in the P1NP biomarker in the 2.5 mg dose group after three months of treatment compared to placebo. P1NP is a biomarker that indicates the rate of new bone formation. Patients in the 2.5 mg dose group also experienced a significant reduction in CTX, a biomarker that indicates the rate of bone resorption. The reduction in CTX corresponds with a reduction in the breakdown of bone and is an important factor for a potential increase in bone mineral density (BMD).
The data, overall, supported the osteoanabolic or bone building effects of EB613 as well as its potential to produce meaningful increases in BMD at six months. Final data from the study, including BMD data are expected to be presented in the second quarter.
EB613, if approved, will be the first oral bone building (osteoanabolic) treatment for osteoporosis, thus providing an oral alternative to daily injections, which should improve patient convenience, compliance and outcomes while lowering the total cost of care.
Entera Bio has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the healthcare sector are BioNTech (BNTX - Free Report) , Atea Pharmaceuticals (AVIR - Free Report) and Repligen Corporation (RGEN - Free Report) . While BioNTech has a Zacks Rank of 1, the other two companies carry a Zacks Rank #2 (Buy).
BioNTech’s earnings estimates have risen from $10.91 per share to $29.44 per share for 2021 and from $7.34 per share to $21.34 per share for 2022 in the past 60 days. The stock is up 138.6% this year so far.
Atea’s earnings per share estimates have increased from $3.70 to $8.37 for 2021 and from $16.14 to $17.21 for 2022 over the past 60 days.
Repligen’s earnings estimates have risen from$1.91 to $2.21 for 2021 and from $2.23 to $2.53 for 2022 over the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>